Banzhaf CA, Phothong W, Suku MLH, et al. - Researchers conducted the study for analyzing the basal cell carcinomas (BCC) response and tolerability following combined ablative fractional laser (AFL) and ingenol mebutate (IM) treatment of low-risk BCCs. For this investigation, 20 individuals with histologically confirmed superficial and nodular BCCs have been treated with combined fractional CO2-laser (10,600 nm) and IM 0.015% or 0.05%, the concentration depending on anatomical location. The authors discovered that 18/20 individuals received a second treatment on day 29 due to clinically detected residual BCC through optical coherence tomography (OCT) or reflectance confocal microscopy (RCM). In five of 20 cases, OCT and RCM presented subclinical BCCs. At day 90, the overall histological cure rate was 70%, corresponding to clinical and OCT/RCM cure rates, and there was a substantial agreement between evaluation methods. Local skin reactions were tolerable, but in the majority of cleared individuals, scarring was observed. Two combined AFL and IM treatments exhibit potential for acceptable tolerability in treating low-risk BCCs. OCT and RCM display promise at a short-term follow-up to identify subclinical BCCs.